Eligibility Acute Schizophrenia NCT01668797

patients age 18 years or older to less than 65 years, inclusive (at time of informed consent)

subjects with a current diagnosis of schizophrenia, as defined by dsm-iv-tr criteria and a history of the illness for at least three years prior to screening (as per subject, family, healthcare provider, or by previous medical records).

subjects with a stable living environment, as demonstrated by the ability to provide contact information for themselves and/or family/friend(s)/caregiver(s).

subjects who showed previous response to antipsychotic treatment in the past year.

subjects who are currently treated with oral or depot antipsychotics other than clozapine or who have had a recent lapse in antipsychotic treatment requiring chronic treatment with antipsychotic medication for stabilization.

subjects who are experiencing a current acute exacerbation of psychotic symptoms requiring stabilization

subjects with a history of relapse and/or exacerbation of symptoms when they are not receiving antipsychotic treatment.

female patients who are breastfeeding or who have a positive pregnancy test (urine) result prior to receiving investigational medicinal product

patients presenting a first episode of schizophrenia based on the clinical judgment of the investigator

patients who are diagnosed with a disease other than schizophrenia (schizoaffective disorder, major depressive disorder, bipolar disorder, posttraumatic stress disorder, anxiety disorder, delirium, dementia, amnesia, or other cognitive disorder) based on current dsm-iv-tr axis ι criteria, or who are diagnosed with a personality disorder (borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial)

subjects experiencing acute depressive symptoms within the past 30 days

subjects with schizophrenia who are considered resistant/refractory to antipsychotic treatment by history

subjects with a significant risk of violent behavior; who represent a risk of committing suicide

subjects with clinically significant tardive dyskinesia

subjects currently treated with insulin for diabetes.